PCM
HCAT icon

Prelude Capital Management’s Health Catalyst HCAT Stock Holding History

Prelude Capital Management’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,000
Closed -$217K – 1710
2022
Q2 		$217K Buy
+15,000
New +$256K 0.01% 1258

Other funds holding HCAT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
DG
Daventry Group New York $133M AUM 32.28% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $317M AUM 37.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Prelude Capital Management's HCAT Position: Q3 2024 in Review

Prelude Capital Management sold out of Health Catalyst (HCAT) in Q3 2024, closing a stake of 18,227 shares — an estimated $116K sold.

Prelude Capital Management first reported a position in HCAT in Q4 2019 and held it in 5 quarters. The position peaked at $548K in Q1 2024. 159 funds tracked by Wall St. Rank hold HCAT as of Q3 2024.

  • Prelude Capital Management reported no remaining Health Catalyst position as of Q3 2024 after selling out during the quarter.
  • Prelude Capital Management sold 18,227 Health Catalyst shares in Q3 2024, an estimated $116K.
  • Prelude Capital Management first reported a position in Health Catalyst in Q4 2019 and held it in 5 quarters.
  • Prelude Capital Management's Health Catalyst position peaked at $548K in Q1 2024.
  • 159 funds tracked by Wall St. Rank held Health Catalyst as of Q3 2024.

Based on Prelude Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.